32
Participants
Start Date
April 7, 2022
Primary Completion Date
July 29, 2022
Study Completion Date
August 26, 2022
Bupivacaine HCI without epinephrine
100 mg administered via injection into the surgical site.
HTX-011
HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.
Luer Lock Applicator
Applicator for instillation.
M3 Emerging Medical Research, LLC, Durham
The Ohio State University Wexner Medical Center - University Hospital, Columbus
Kansas Spine and Specialty Hospital, Wichita
Spine Institute of Louisiana, Shreveport
Houston Heights Hospital, Houston
First Surgical Hospital, Bellaire
South Texas Spine & Surgical Center, San Antonio
Austin Neurosurgeons, Austin
JBR Clinical Research, Salt Lake City
Arizona Research Center, Phoenix
Lotus Clinical Research, LLC, Pasadena
Overlook Medical Center, Summit
Lead Sponsor
Heron Therapeutics
INDUSTRY